Evidence map›Paper›PMID 31881856›Full record

Trial reportBMC cancer2019

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.

Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima and 2 more

Registry-linked trialOpen access · goldAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05266820 (TACTIC), which is not on this map. Cited by 30 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 5 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05266820 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma

TypeinterventionalSponsorFujian Cancer HospitalRan2021 to 2023Enrolled120ConditionsMetastatic Colorectal CancerArmsThalidomide, TAS-102
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Daisuke KotaniDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yasutoshi KubokiDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. ykuboki@east.ncc.go.jp.
Satoshi HorasawaDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Asumi KanekoDepartment of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshiaki NakamuraDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Akihito KawazoeDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hideaki BandoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroya TaniguchiDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kohei ShitaraDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takashi KojimaDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Akihito TsujiDepartment of Medical Oncology, Graduated School of Medicine, Kagawa University, Takamatsu, Japan.
Takayuki YoshinoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
National Cancer Center Hospital East · JPAichi Cancer Center · JPKagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings.

methodsRecords of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution.

resultsTotally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3-5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8-2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48-0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444).

conclusionsIn real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities.

trial registrationRetrospectively registered.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDisease-Free SurvivalDrug CombinationsFemaleHumansMaleMiddle AgedNeoplasm MetastasisPyrrolidinesRetrospective StudiesBevacizumabDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilLonsurfmCRCTAS-102Trifluridine/tipiracil plus bevacizumab

Identifiers

PMID31881856
PMCPMC6935149
OpenAlexW2998254999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.